VQW-765 Phase 3 trial

Latest Post

Bristol Myers Squibb Raises 2026 Revenue Forecast as Newer Drugs Drive Q3 Growth Laurus Labs to Acquire 60% Stake in Canadian Biotech Firm Galenvs Sciences for $3.75 Million Fortis Healthcare Acquires Suguna Hospital in Bengaluru for ₹277 Crore Ro Launches Robin AI Health Agent to Personalise Medication and Patient Care Recommendations Laurus Labs Q2 Results: Net Profit Surges 126% to ₹441 Crore as Revenue Grows 33%

VQW-765 Clinical Trial Results: Disappointing Phase 3 Miss

October 16, 2026 Simone Lamb

VQW-765 clinical trial results: Vanda’s Phase 3 social anxiety study missed its goals and the programme is on hold. What the data show.

You missed

Bristol Myers Squibb Raises 2026 Revenue Forecast as Newer Drugs Drive Q3 Growth

October 30, 2026 Simone Lamb

Laurus Labs to Acquire 60% Stake in Canadian Biotech Firm Galenvs Sciences for $3.75 Million

October 30, 2026 Simone Lamb

Healthcare Services

Fortis Healthcare Acquires Suguna Hospital in Bengaluru for ₹277 Crore

October 30, 2026 Simone Lamb

Ro Launches Robin AI Health Agent to Personalise Medication and Patient Care Recommendations

October 30, 2026 Simone Lamb